drugset
drugset / Trial / NCT01750814

To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults

NCT01750814 ↗

Phase 3 Completed 400 enrolled Green Cross Corporation
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The primary objective is to demonstrate the immunological non-inferiority between GC3102C and GC FLU inj. influenza vaccines by assessing geometric mean titers(GMTs) in healthy adults

Timeline

Start
2013-06
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator GC FLU inj. Vaccine 0.5 ml Intramuscular
Subject GC3102C Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.